Member Info for bignose58

As was to be expected, 0.0% "Against". "For" was a massive 194,895,686 (100.00%) votes

There was absolutely no point in putting it to the vote.

Morning The.Italian.

At this rate, the re-rate which Jamie mentioned in his response to my email, will probably only lift the price back to 1HK$ :-)

Yet again, we are back to the lowest market cap of 16mill squid. Its just sad that given all the previous dilutions since the PLE takeover, we are effectively at a market cap of less than 4mill squid.

Will China be that impressive ? If we go by the EU, then I would say not. Mind you, WangBang seems quite optimistic on their possible sales figures Does this mean they have actually some some proper market research rather than rely on the unrealistic noise about; since there are the same number of sufferers as ED sufferers, sales should be the same ?

Only time will tell, but still no indication of approval other than the end of June. Could this be a date provided by the authorities as a standard timeline given all Q&A's were completed at the end of 2025 ? One can only speculate.

Incidentally, JG has not responded to my email response. Probably too embarrassed on how bad a job he is doing as CEO. If he had any morals, he would have resigned for his consistently bad performance on missed timelines which are more regular than trains. ;-)

Continued...

I also now read that the company wants to propose the adoption of an RSU Scheme, which is with the purpose of recognising and rewarding certain eligible participants.

I am at a loss as to rewarding who and for what. The FDA NDA submission is years behind schedule with still no end in sight. China is now over 3 years behind and still no sign of approval (you do comment about potential, but the same comment was given about Europe and yet it has been nothing other than a disappointment). Orient appears to have stopped in its tracks and the out licensing for certain countries in LATAM, Asia Pacific (including Australia), South Africa and the Middle East region which had supposedly entered into nonbinding heads of terms in 2014 have made little progress up to today.

Given that long-term supporting shareholders have lost so much of their investment in the last 14 years, it is quite clear that all the company statements in the past annual/half yearly reports about how excited the BOD is and how they thank shareholders for their support, actually means very little. Surely the RSU scheme, with consideration of shareholder losses, could have been announced at the end of the year after the supposed rerate and the China income stream is in place rather than just give shareholders a slap in the face.

Yes, I am disgruntled, which I make no apologies for since I feel the company has let shareholders down with the constant jam tomorrow statements.

Regards

Mr BigNose

Good morning Jamie.

Thank you for the response to my email, which provides a little positivity.

Regarding the DBC, I apologise for my punctuation. A new paragraph was supposed to start with "Overnight", meaning: Overnight, the company (meaning RPG and not DBC) became Cannabinoid investors,... The email was written in word and copied over, so I can only assume some formatting was altered during the copy and paste process.

With regard to PSNW, although Recordati may have the responsibility to use their own manufacturer, it was quite obvious from the onset that they would use PSNW given that RPG had already stated in 2014 that PSNW was engaged as the Company’s European-based manufacturing partner, otherwise something else would have been stated regarding Recordati. As such, RPG had a responsibility to advise shareholders of the administration issues given they had a substantial impact on shareholder value from a necessary placing. If there were no issue and Recordati still wished to change manufacturer, PSNW could have still supplied cans whilst Recordati were entering into a new agreement with Genetic and obtaining EU approval. This would have had no delay with the European 2nd rollout China and Orient and more than likely no requirement for dilution given China would have had 18months of sales.

That’s said, there has been no update on progress with the change in manufacturer by Orient. Why was this? Ever since Orient entered into a license agreement, there appears to be little progress, which will now be further delayed due to the PSNW debacle. Has there been any progress on either of Orients regions with regard to approval progress?

With regard to production, you again only mention production possibilities but do not elaborate on current upscaling. The OTC approval announcement did mention upscaling to 50k cans, but given the wording used (with the aim), which is not that specific on timeline, one has to assume batches would still only be every 4 months. At least with PSNW we knew they had upscaled to 50k cans which could be produced every 6 to 7 weeks (you actually provided me with sometime ago a complete timeline breakdown on batch production). Can you please elaborate on what the current upscaling is or is it as I have indicated ?

Although Genetic is in the process of building an additional production line, this surely will take close to a couple of years before it is built, approved and up and running, which I base on the information you provided before with respect to a n additional production line with PSNW. Will the time needed by Genetic be any different and when are they targeting to complete this alleged work?

Continued.....

Dougie.

You are not wrong there. The below is an extract from the PLE 2014 interims, signed off by JG. Note: Both parties had entered into non-binding heads of terms. And that was 12 years ago !!!

Discussions and negotiations are currently taking place with:

(i) A global pharmaceutical company for ‘out licensing’ the grant of rights by Plethora in respect of PSD502™ for certain countries in LATAM, Asia Pacific (including Australia) and South Africa. The parties have entered into non-binding heads of terms and have moved into discussions on the license agreement which anticipate an up-front payment to Plethora followed by additional payments upon the achievement of certain milestones plus royalties linked to sales.

(ii) A multinational pharmaceutical company for ‘out licensing’ the grant of rights by Plethora in respect of PSD502™ for countries in the Middle East region. The parties have entered into nonbinding heads of terms and have moved into discussions on the license agreement which anticipate an up-front payment to Plethora followed by additional payments upon the achievement of certain milestones plus royalties linked to sales.

On 4 May 2026, the board (the “Board”) of directors (the “Directors”) of Regent Pacific Group Limited (the “Company”, together with its subsidiaries, the “Group”) has resolved to propose the adoption of a restricted share unit scheme (the “RSU Scheme”) by the Company, with the purpose of recognising and rewarding the contribution of certain eligible participants to the growth and development of the Group.

Yet another legal way to move shares out of PI hands. What contribution. Everything RPG has touched has been delayed.

Certainly no point in voting given Jim will just proxy JG with his voting rights.

They are doing this now because the Chinese approval is coming and there is supposedly (see my previous posts) going to be a rerate.

So, he didn't answer my questions regarding advising the market about PSNW, which, they were obliged to do, given that they used PSNW to manufacture the cans in the first place and any licensee would automatically use them until they could sort out their own.

The fact that PSNW went in to administration, which meant they would not run in parallel producing cans whilst an additional manufacturer was approved, resulted in the need for a further placing with associated dilution. i.e financial impact to the SP.

And again, bluff on can production. 23mill cans in what, probably 20 years time? What I want to know is how many are they producing now so I can gauge how Genetic can meet the needs of Europe and China.(As well as Orient which was never addressed).

Anyway, there you have it. I suppose I was lucky to even receive a response.... :-)

......... We are also in discussions with a prospective partner covering the Middle East, LATAM and South America, who is currently conducting due diligence. Should these discussions progress to agreement, an appropriate announcement will be made in due course.

Finally, the Group has developed a targeted investor relations and PR programme, which is intended to be implemented upon regulatory approval in China, with the objective of supporting a re-rating of the Company.

All the best,

Jamie

Many thanks for your email.

We fully recognise and share your disappointment regarding the EU sales performance by Recordati. By way of context, it may be helpful to reiterate the Company’s business model.

Regent Pacific operates a focused model centered on the development and strategic out-licensing of Fortacin / Senstend. The Group has successfully developed Fortacin through its in-house R&D platform and has subsequently entered into territorial licensing arrangements with established pharmaceutical partners.

Under these agreements, the Group receives upfront consideration, regulatory and commercial milestone payments, and ongoing royalties based on net sales within the licensed territories. Our partners assume full responsibility for all downstream activities, including manufacturing, regulatory approval, marketing, distribution and sales. The Group is not involved in these activities; they are undertaken by our partners at their own risk and cost, with the Company receiving the contracted economic benefits.

This partnership-led approach enables the Group to leverage the scale, infrastructure and commercial expertise of leading pharmaceutical companies, while maintaining a lean operating structure and a less capital intensive framework.

With respect to manufacturing, the contract manufacturing organisation (“CMO”) Genetic was engaged by Recordati. The Group does not contract directly with Genetic or any other CMO, and manufacturing risk and cost remain the responsibility of our pharmaceutical partners. We understand from Genetic that it has capacity to produce approximately 23 million Fortacin canisters per annum and is targeting an additional c.20 million units through a new PMDI production line currently under construction.

The license agreement with Recordati remains in force and unchanged since execution.

In China, our partner Fosun Pharma continues to progress the regulatory approval process. Based on their latest guidance, they remain hopeful of securing approval by the end of Q2. To date, Fosun has addressed over 35 queries from the NMPA and CDE across clinical, non-clinical and CMC sections and is progressing towards completion.

With regard to DLI, the business has currently secured eight customers, and further details are available on its website. The longevity sector remains at an early stage of development, and we are encouraged by the initial commercial traction achieved by a lean team.

Looking ahead, the potential approval of Senstend in China represents a significant opportunity for the Group, given the size of the market and Fosun’s view of the product’s commercial potential.

In parallel, we are actively engaging with potential strategic pharmaceutical partners for the US market who would undertake Phase III studies, regulatory approval and subsequent commercialisation. This remains a key strategic priority. ...... Continues

What I meant was 50% dilution, but one’s investment would need to increase by 100% to recoup the loss.

I apologise for scaring anyone … lol

Exactly my point when I responded to Laura, who obviously is ramping and just gambling. This is about market cap. It has nothing to do with, ‘The share price includes for the possibility of dilution”.

Given the last cash call was for around 2.3 mill. It can be assumed they would need about the same amount this time too.

Since the current market cap = 4.6mill, its painfully clear they would need to dilute by 100%.

Any astute investor, would not consider buying now, however. Hardened gamblers who are happy with the odds stacked against them may consider it, although I would think most of those wouldn’t.

Good for you, but nobody actually cares.

Nope

Originally the agreement between PLE and Recordati was for a 6 dose can, which we know failed. Once the 12 dose can was developed and approved, an addendum with Recordati was made and announced on 14th August 2018. This agreement was to last for 10 years from the date of first sales, which was announced on the 9th February 2018 and which still stated tiered percentage royalties on net sales, ranging from the mid-teens to the mid-twenties from first commercial sale, thereafter, at a single digit percentage royalty rate.

Meaning that up until Feb 2028, the above would still be valid, however. There was no mention of any OTC approval within the agreement. which we know was approved on 27th August 2020, by way of an announcement on 3rd Sep 2020. The announcement also mentions that they aim to increase can batch size to 50k can/ batch. Yet, no further information was given to say this is what indeed happened. Also, as far as shareholders are concerned a batch still would take 4 months to produce. (although we know it took PSNW 72 days / batch, or so we were led to believe).

Since the received Royalty figure in the financials is only 228k USD, it is fair to assume, as I mentioned before, that a new agreement must be in place, given PLE is supposed to receive royalty payments of mid teens to mid 20's.

Anyway, just some food for thought.

On Fri 28th May 2015, PLE announced by way of RNS No: 5178X

New Drug Application (NDA) with the US FDA

Significant progress has been made in preparation for the start of the supplementary Phase 3 clinical study required by the FDA for the completion of a new dossier for approval.

Interactions with the FDA have been frequent (once per month) for the last quarter with agreement achieved on the final form and content of the Patient Reported Outcome (PRO or PE) questionnaire or the "copyrightable" PEBEQ (Premature Ejaculation Bothersome Evaluation Questionnaire) to be used in the supplementary study.

The final testing stage of PRO development, the "quantitative stage" has now begun and the target remains steadfast for its finalization in November 2015 (FDA submission). The clinical study is anticipated to start in Q1 2016 with the final audited report expected in Q1 2017. It is therefore expected that the NDA will be filed with the US FDA in Q1 2017.

Strange. It is now 2026 and phase III still has not started. (10 years on)

ORIENT :O)

And for ORENT.

A low teens royalty on net sales; and a lower percentage royalty on net sales will apply in certain circumstances where a generic product has successfully entered and impacted the market in the Territory.

But as of today, there has been no mention of any import license applications or approvals for any of Orients regions, which will be delayed due to updating the manufacturing list.

Bothwell,

Not sure why you would post that given it doesn't make any ref to regions involved. For Europe, the actual % is far less than 15% (see royalty revenue for 90k cans/year in the recent financials). The US is an unknown and for China, according to the agreement announcement on Dec 3rd 2018, PLE would receive 25 percent of net receipts; and tiered percentage royalties on net sales.

It also mentions that on NMPA approval the company would receive up to 6mill USD, which, for some reason has , over the years, reduced to 5mill.(From the financials this year - Upon approval by the NMPA, US$5 million - before deduction of PRC withholding tax) - shall be payable to the Group from Wanbang Biopharmaceutical).

Yes, granted it states up to 6mill, but do we really believe that statement is written in the signed agreement....no, I don't think so. Obviously a deliberate typo back in 2018.

Since they can get a typo wrong which reduces the payment by some %, are we to assume the net receipt and royalty payments are also typos ?

FYI.

It seem PLE has recently paid off debts from 2007/2010 and 2013

3 statements by ROMERO TAYONG and 1 statement by DENHAM EKE

https://find-and-update.company-information.service.gov.uk/company/04977609/filing-history

Nothing in the financials about them though.

I don't actually expect a response since there are too many truths. Of course, there are many more which I chose not to include this time, however. At least I wrote something and sent it to them, which is now logged, to let them know how one of their shareholders feels. I have nothing to lose in doing so.

It's all very well complaining here, but its worth complaining to them directly since they obviously feel they are performing their fiduciary duties well, which we know they are definitely not. Their constant lies and misleading information speaks for itself.

It is also worth noting that repeated lies and misinformation can become accepted as truth (often referred to as the illusory truth effect), which is a well-documented phenomenon in psychology, where familiarity with a statement/s increases its/their perceived validity, regardless of accuracy. which they have been doing for the last 12 years and which both JM and JG are experts at.